Literature DB >> 29053210

A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.

Yoshiaki Kinoshita1,2, Tomoyuki Hida3, Makoto Hamasaki1, Shinji Matsumoto1, Ayuko Sato4, Tohru Tsujimura4, Kunimitsu Kawahara5, Kenzo Hiroshima6, Yoshinao Oda3, Kazuki Nabeshima1.   

Abstract

BACKGROUND: Homozygous deletion of 9p21 detected by fluorescence in situ hybridization (FISH) and loss of BRCA1-associated protein 1 (BAP1) expression detected by immunohistochemistry (IHC) are useful for the differentiation between malignant pleural mesothelioma (MPM) and reactive mesothelial hyperplasia. The authors previously described that IHC expression of the protein product of the methylthioadenosine phosphorylase (MTAP) gene, which is localized in the 9p21 chromosomal region, was correlated with the deletion status of 9p21 FISH in MPM tissues. In the current study, the authors investigated whether a combination of MTAP and BAP1 IHC could distinguish MPM from reactive mesothelial cells (RMC) in cell blocks obtained from pleural effusions.
METHODS: The authors examined IHC expression of MTAP and BAP1 in cell blocks obtained from pleural effusions of 45 cases of MPM and 21 cases of reactive mesothelial hyperplasia. Furthermore, IHC expression of MTAP was compared with the deletion status of 9p21 FISH.
RESULTS: MTAP and BAP1 IHC differentiated MPM from RMC with 100% specificity for both and sensitivities of 42.2% and 60.0%, respectively. The combination of MTAP and BAP1 IHC yielded a sensitivity of 77.8%, which was higher than that of BAP1 IHC alone or 9p21 FISH alone (62.2%). Moreover, a high degree of concordance was observed between the results of MTAP IHC and 9p21 FISH in cell blocks.
CONCLUSIONS: A combination of MTAP and BAP1 IHC in cell blocks from pleural effusions appears to be a reliable and useful method for differentiating MPM cells from RMC and can be used in the routine diagnosis of MPM. Cancer Cytopathol 2018;126:54-63.
© 2017 American Cancer Society. © 2017 American Cancer Society.

Entities:  

Keywords:  9p21 fluorescence in situ hybridization; cell block; malignant pleural mesothelioma; pleural effusion; reactive mesothelial hyperplasia

Mesh:

Substances:

Year:  2017        PMID: 29053210     DOI: 10.1002/cncy.21928

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  11 in total

1.  Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.

Authors:  Yoshiaki Kinoshita; Makoto Hamasaki; Masayo Yoshimura; Shinji Matsumoto; Akinori Iwasaki; Kazuki Nabeshima
Journal:  Mod Pathol       Date:  2019-06-23       Impact factor: 7.842

Review 2.  Pleural mesothelioma classification update.

Authors:  Mary Beth Beasley; Francoise Galateau-Salle; Sanja Dacic
Journal:  Virchows Arch       Date:  2021-01-21       Impact factor: 4.064

Review 3.  Pleural mesothelioma classification-update and challenges.

Authors:  Sanja Dacic
Journal:  Mod Pathol       Date:  2021-08-31       Impact factor: 7.842

4.  Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma.

Authors:  David B Chapel; Jason L Hornick; Julianne Barlow; Raphael Bueno; Lynette M Sholl
Journal:  Mod Pathol       Date:  2022-04-22       Impact factor: 8.209

Review 5.  Genomics and Epigenetics of Malignant Mesothelioma.

Authors:  Adam P Sage; Victor D Martinez; Brenda C Minatel; Michelle E Pewarchuk; Erin A Marshall; Gavin M MacAulay; Roland Hubaux; Dustin D Pearson; Aaron A Goodarzi; Graham Dellaire; Wan L Lam
Journal:  High Throughput       Date:  2018-07-27

6.  5-hydroxymethylcytosine but not MTAP methylation status can stratify malignant pleural mesothelioma based on the lineage of origin.

Authors:  Matteo Bosio; Elena Salvaterra; Francesca Datturi; Patrizia Morbini; Michele Zorzetto; Simona Inghilleri; Stefano Tomaselli; Patrizia Mangiarotti; Federica Meloni; Isa Cerveri; Giulia Maria Stella
Journal:  Multidiscip Respir Med       Date:  2018-08-02

7.  Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis.

Authors:  Toshiyuki Enomoto; Mikiko Aoki; Makoto Hamasaki; Hiroshi Abe; Masani Nonaka; Tooru Inoue; Kazuki Nabeshima
Journal:  Neurol Med Chir (Tokyo)       Date:  2020-01-03       Impact factor: 1.742

8.  Indian Academy of Cytologists Guidelines for Collection, Preparation, Interpretation, and Reporting of Serous Effusion Fluid Samples.

Authors:  Radhika Srinivasan; Bharat Rekhi; Arvind Rajwanshi; Saleem Pathuthara; Sandeep Mathur; Deepali Jain; Nalini Gupta; Upasana Gautam; Naresh Rai; Vijay Shrawan Nijhawan; Venkat Iyer; Pranab Dey; Prabal Deb; Dev Prasoon
Journal:  J Cytol       Date:  2019-12-23       Impact factor: 1.000

Review 9.  Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.

Authors:  David B Chapel; Jefree J Schulte; Aliya N Husain; Thomas Krausz
Journal:  Transl Lung Cancer Res       Date:  2020-02

10.  Predicting Survival for Patients with Malignant Pleural Effusion: Development of the CONCH Prognostic Model.

Authors:  Xin Zhang; Feng-Shuang Yi; Huan-Zhong Shi
Journal:  Cancer Manag Res       Date:  2021-06-14       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.